Key findings from the Phase 2 trial included: Dose-dependent weight loss , with greater reductions observed at higher doses Significant improvements in waist circumference , blood pressure , and lipid profiles Reductions in fasting glucose and insulin resistance markers, though the clinical significance of these findings in people with type 2 diabetes requires further investigation Weight loss appeared to continue throughout the 48-week period without a clear plateau at the highest doses Whilst these results are encouraging, it is important to contextualise them appropriately
High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database
Enter any vial amount, any water volume, and any target dose, and the calculator returns your exact concentration, volume per dose, syringe units, and total doses per vial
Ethical clarity helps reduce litigation risk
Semaglutide and related drugs change addictive behaviors in mice and rats One recent study on the potential for semaglutide to curb addiction looked at rats and mice that had already developed excessive alcohol drinking behavior
doi: 10.1159/000457332
